Cizzle Biotechnology Holdings PLC Update on Put Option with Conduit (1933N)

TIDMCIZ

RNS Number : 1933N

Cizzle Biotechnology Holdings PLC

21 September 2023

21 September 2023

Cizzle Biotechnology Holdings plc

("Cizzle" or "the Company")

Update on Put Option with Conduit

Shareholder Approval for Conduit-Murphy Merger and NASDAQ Listing

Cizzle Biotechnology Holdings plc, the UK based diagnostics developer, announces a further update regarding the Company's put option to sell its 5% economic interest and royalty sharing agreement in the AZD 1656 asset to treat inflammatory pulmonary and cardiovascular disease ("Option") to Conduit Pharmaceuticals ("Conduit") for a total consideration of GBP3.25 million, to be satisfied through the issuance of new shares in Conduit (the "Option") and its prospective parent Murphy Canyon Acquisition Corp. (NASDAQ: MURF) ("Murphy").

Cizzle announced on 8 September that 2023 that Murphy planned to hold a special meeting of its shareholders to provide their approval for the merger of Conduit and Murphy on Wednesday 20 September 2023 . At the meeting held yesterday the merger was approved and as a consequence it is expected to complete today. Assuming the merger completes as expected, the Conduit-Murphy merged business, thereafter to be called Conduit, will become a publicly traded company on NASDAQ in the USA tomorrow, 22 September 2023.

Should Cizzle exercise its Option, the Company will hold shares in the NASDAQ listed merged business. The new shares in Conduit to be provided to Cizzle pursuant to the exercise of the Option will not be subject to any restrictions.

Enquiries:

 
 Cizzle Biotechnology Holdings     Via IFC Advisory 
  plc 
 Allan Syms (Executive Chairman) 
 
 
 Allenby Capital Limited    [phone] 
 John Depasquale 
 George Payne 
 
 
 Novum Securities Limited    [phone] 
 Colin Rowbury 
  Jon Bellis 
 
 
 IFC Advisory Limited    [phone] 
 Tim Metcalfe 
 Florence Chandler 
 

About Cizzle Biotechnology

Cizzle is developing a blood test for the early detection of lung cancer. The Company is a spin- out from the University of York, founded in 2006, around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see https://cizzlebiotechnology.com You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

About Conduit Pharmaceuticals Limited

Led by highly experienced pharma executives, Conduit is a clinical stage specialty biopharmaceutical company, addressing unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. The development pipeline includes a glucokinase inhibitor in a number of Phase 2 ready autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant. Conduit's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDSESSIFEDSEEU

(END) Dow Jones Newswires

September 21, 2023 02:00 ET (06:00 GMT)